Table 1. Demographic characteristics in 18F-florbetapir positive versus negative scans.
| 18F-florbetapir assessment method | Expert visual rating | Composite ROI SUVr | ||||
|---|---|---|---|---|---|---|
| Scan result (N) | Negative (46) | Positive (15) | Statistic | < 1.10 (44) | ≥ 1.10 (17) | Statistic |
| Age of onset, y | 59.2 | 62.6 | 0.20 | 57.8 | 65.8 | 0.001 |
| (56.7 to 61.6) | (56.5 to 68.8) | (55.5 to 60.1) | (60.6 to 71.0) | |||
| Age at scan time, y | 66.2 | 69.1 | 0.24 | 65.0 | 72.1 | 0.002 |
| (64.2 to 68.3) | (63.0 to 75.3) | (62.9 to 67.0) | (67.3 to 76.9) | |||
| Sex, male / female | 31 / 15 | 13 / 2 | 0.20 | 32 / 12 | 12 / 5 | 1.00 |
| APOE ε4, % present | 32.6% | 33.3% | 1.00 | 27.3% | 47.1% | 0.22 |
| Education, y | 16.6 | 15.3 | 0.07 | 16.3 | 16.2 | 0.90 |
| (16.0 to 17.3) | (13.9 to 16.8) | (15.6 to 17.1) | (15.1 to 17.3) | |||
| Disease duration, y | 7.8 | 7.5 | 0.87 | 7.9 | 7.2 | 0.63 |
| (6.3 to 9.3) | (5.6 to 9.5) | (6.4 to 9.4) | (5.3 to 9.2) | |||
| PIGD phenotype, % present | 59.1% | 60.0% | 1.00 | 60.5% | 56.3% | 0.78 |
| UPDRS part 3 score | 18.5 | 22.1 | 0.20 | 17.8 | 23.4 | 0.04 |
| (15.8 to 21.2) | (16.8 to 27.5) | (15.0 to 20.7) | (19.0 to 27.9) | |||
Significant differences by two-sample T-test or Fisher’s exact test indicated in bold prior to correction for multiple comparisons. All data are mean (95% C.I.) unless otherwise specified.